Enveda Biosciences Stock

envedabio.comHealthcare / Healthcare softwareFounded: 2019Funding to Date: $183.8MM

Enveda Biosciences is a drug discovery platform focusing on natural biological activity as a means of development. Their current pipeline includes pain and topical dermatology areas. Enveda Biosciences was founded in 2019 by Viswa Colluru Ph.D. and Pieter Dorrestein and is headquartered in Boulder, CO.

Register To Buy and Sell Shares

For more details on financing and valuation for Enveda Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Enveda Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Enveda Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Viswa Colluru Ph.D
Co-Founder, Chief Executive Officer & Board Member
Joe Rokicki Ph.D
Chief Technology Officer
Sotirios Karathanasis Ph.D
Chief Science Officer
Vanitha Sekar
Chief Business Officer
August Allen
Chief Platform Officer
Mark Deeg Ph.D
Chief Medical Officer

Board Members

Harsh Patel
Wireframe Ventures
Shaquille Vayda
Lux Capital

Frequently Asked Questions About Enveda Biosciences’ Stock

Can you buy Enveda Biosciences’ stock?
Enveda Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Enveda Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Enveda Biosciences’ stock?
Yes, you can sell stock of a private company like Enveda Biosciences. Forge can help you sell your Enveda Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Enveda Biosciences’ stock price?
Enveda Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Enveda Biosciences’ private market stock price with Forge Data.
What is Enveda Biosciences’ stock ticker symbol?
Enveda Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Enveda’s Matured Platform Drives Toward Three INDs in 2023
Since its launch in 2019, Enveda Biosciences has raised $124 million to advance its pipeline of nature-based small molecules targeting difficult therapeutic problems, most recently closing a Series B round in the midst of a stingy financing environment.
Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer
Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer. Dr. Deeg is a medical and pharmaceutical leader with broad experience developing drugs and digital therapeutics at companies from biopharma startups to pharmaceutical giants like Eli Lilly & Co., where he spent more than a decade.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.